Telix Pharmaceuticals' Goz نتix Gets CMS Pass-Through Status
Ticker: TLPPF · Form: 6-K · Filed: Sep 23, 2025 · CIK: 2007191
| Field | Detail |
|---|---|
| Company | Telix Pharmaceuticals Ltd (TLPPF) |
| Form Type | 6-K |
| Filed Date | Sep 23, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | bullish |
Sentiment: bullish
Topics: regulatory-approval, reimbursement, healthcare, oncology
TL;DR
Telix's Goz نتix gets Medicare/Medicaid coverage starting Oct 1st, big win for US access!
AI Summary
On September 23, 2025, Telix Pharmaceuticals Limited announced that the Centers for Medicare & Medicaid Services (CMS) has granted transitional pass-through status for its prostate cancer imaging agent, Goz نتix. This designation is effective from October 1, 2025, and is expected to facilitate broader patient access and reimbursement for the diagnostic tool.
Why It Matters
This CMS transitional pass-through status is crucial for Goz نتix as it ensures Medicare and Medicaid will cover the product, significantly increasing its accessibility for eligible patients in the United States.
Risk Assessment
Risk Level: low — The filing is an informational update regarding regulatory status and does not involve significant financial transactions or operational changes that would inherently increase risk.
Key Players & Entities
- Telix Pharmaceuticals Limited (company) — Registrant
- Goz نتix (product) — Prostate cancer imaging agent
- Centers for Medicare & Medicaid Services (CMS) (company) — Regulatory body granting status
- September 23, 2025 (date) — Date of announcement
- October 1, 2025 (date) — Effective date of pass-through status
FAQ
What is the significance of the CMS transitional pass-through status for Goz نتix?
The CMS transitional pass-through status, effective October 1, 2025, ensures that Medicare and Medicaid will provide reimbursement for Goz نتix, facilitating broader patient access in the United States.
When did Telix Pharmaceuticals Limited announce this news?
Telix Pharmaceuticals Limited announced this news on September 23, 2025.
What is Goz نتix used for?
Goz نتix is a prostate cancer imaging agent.
Where is Telix Pharmaceuticals Limited based?
Telix Pharmaceuticals Limited is based in North Melbourne, Victoria, Australia.
What form was filed with the SEC regarding this announcement?
Telix Pharmaceuticals Limited filed a Form 6-K with the SEC to report this announcement.
Filing Stats: 235 words · 1 min read · ~1 pages · Grade level 15.1 · Accepted 2025-09-23 16:21:09
Filing Documents
- gozkpass.htm (6-K) — 11KB
- gozpasspr.htm (EX-99.1) — 0KB
- gozpasspr1.jpg (GRAPHIC) — 354KB
- gozpasspr2.jpg (GRAPHIC) — 287KB
- gozpasspr3.jpg (GRAPHIC) — 216KB
- 0002007191-25-000069.txt ( ) — 1192KB
SIGNATURES
SIGNATURES   Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.           Telix Pharmaceuticals Limited       Date: September 23, 2025 By: /s/ Genevieve Ryan     Name: Genevieve Ryan     Title: Company Secretary